Turoctocog alfa

Generic Name
Turoctocog alfa
Brand Names
Novoeight, Zonovate, NovoEight
Drug Type
Biotech
Chemical Formula
-
CAS Number
1192451-26-5
Unique Ingredient Identifier
969NZA3X9T
Background

Turoctocog alfa is a recombinant factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the N-terminus and 11 amino acids from the C-terminus of the naturally occurring B-domain. Turoctocog alfa is produced in Chinese hamster ovary (CHO) cells without addition of any human- or animal-derived materials. During sec...

Indication

Turoctocog alfa is indicated for the treatment and prophylaxis of bleedings in patients presenting hemophilia A. The treatment with turoctocog alfa is related with its use to control bleeding episodes or as a perioperative management. Hemophilia A is a hereditary hemorrhagic disorder generated by the congenital deficit of the coagulation factor VIII. This di...

Associated Conditions
Bleeding
Associated Therapies
-
Clinical Trials
Related News

Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A

First Posted Date
2012-09-26
Last Posted Date
2017-02-10
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
15
Registration Number
NCT01692925
Locations
🇪🇸

Novo Nordisk Investigational Site, Madrid, Spain

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A

First Posted Date
2011-12-16
Last Posted Date
2020-11-30
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
60
Registration Number
NCT01493778
Locations
🇹🇷

Novo Nordisk Investigational Site, Samsun, Turkey

A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A

First Posted Date
2011-06-03
Last Posted Date
2017-02-10
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
4
Registration Number
NCT01365520
Locations
🇬🇧

Novo Nordisk Investigational Site, London, United Kingdom

A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543

First Posted Date
2010-11-10
Last Posted Date
2017-02-10
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
6
Registration Number
NCT01238367
Locations
🇯🇵

Novo Nordisk Investigational Site, Suginami-ku, Tokyo, Japan

Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A

First Posted Date
2010-06-07
Last Posted Date
2017-03-17
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
65
Registration Number
NCT01138501
Locations
🇹🇷

Novo Nordisk Investigational Site, Izmit, Turkey

Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015

First Posted Date
2009-09-25
Last Posted Date
2017-07-27
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
214
Registration Number
NCT00984126
Locations
🇬🇧

Novo Nordisk Investigational Site, Manchester, United Kingdom

Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects

First Posted Date
2009-02-10
Last Posted Date
2017-03-17
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
150
Registration Number
NCT00840086
Locations
🇬🇧

Novo Nordisk Investigational Site, Manchester, United Kingdom

Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects

First Posted Date
2009-02-05
Last Posted Date
2017-02-10
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
23
Registration Number
NCT00837356
Locations
🇨🇭

Novo Nordisk Investigational Site, Zürich, Switzerland

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy